참고문헌
- Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012;33(6):920-80. https://doi.org/10.1210/er.2012-1030
- Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 2007;109(10):1972-9. https://doi.org/10.1002/cncr.22635
- Abraham P, Acharya S. Current and emerging treatment options for Graves' hyperthyroidism. Ther Clin Risk Manag 2010;6:29-40.
- Lewis A, Atkinson B, Bell P, Courtney H, McCance D, Mullan K, et al. Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen. Ulster Med J 2013;82(2):85-8.
- Gupta SK, McGrath S, Rogers K, Attia J, Lewis G, Viswanathan S, et al. Fixed dose (555 MBq; 15 mCi) radioiodine for the treatment of hyperthyroidism: outcome and its predictors. Intern Med J 2010;40(12):854-7. https://doi.org/10.1111/j.1445-5994.2010.02348.x
- Turner J, Sadler W, Brownlie B, Rogers T. Radioiodine therapy for Graves' disease: multivariate analysis of pretreatment parameters and early outcome. Eur J Nucl Med 1985;11(6-7):191-3. https://doi.org/10.1007/BF00279066
- Farrar JJ, Toft AD. Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinol (Oxf) 1991;35(3):207-12. https://doi.org/10.1111/j.1365-2265.1991.tb03523.x
- Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995;25(3):186-93. https://doi.org/10.1111/j.1365-2362.1995.tb01547.x
- Jarlov AE, Hegedus L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf) 1995;43(3):325-9. https://doi.org/10.1111/j.1365-2265.1995.tb02039.x
- Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011;21(6):593-646. https://doi.org/10.1089/thy.2010.0417
- Morris JC 3rd, Hay ID, Nelson RE, Jiang NS. Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods. Mayo Clin Proc 1988;63(7):707-17. https://doi.org/10.1016/S0025-6196(12)65533-5
- Moon JH, Yi KH. The diagnosis and management of hyperthyroidism in Korea: consensus report of the korean thyroid association. Endocrinol Metab (Seoul) 2013;28(4):275-9. https://doi.org/10.3803/EnM.2013.28.4.275
- Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative effectiveness of treatment choices for Graves' hyperthyroidism: a historical cohort study. Thyroid 2017;27(4):497-505. https://doi.org/10.1089/thy.2016.0343
- Sfiligoj D, Gaberscek S, Mekjavic PJ, Pirnat E, Zaletel K. Factors influencing the success of radioiodine therapy in patients with Graves' disease. Nucl Med Commun 2015;36(6):560-5. https://doi.org/10.1097/MNM.0000000000000285
- Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) 2004;61(5):641-8. https://doi.org/10.1111/j.1365-2265.2004.02152.x
- Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002;87(3):1073-7. https://doi.org/10.1210/jc.87.3.1073
- Goolden AW, Fraser TR. Treatment of thyrotoxicosis with low doses of radioactive iodine. Br Med J 1969;3(5668):442-3. https://doi.org/10.1136/bmj.3.5668.442
- Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease. J Clin Endocrinol Metab 2007;92(9):3547-52. https://doi.org/10.1210/jc.2007-0879
- Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics 2003;111(4 Pt 1):745-9. https://doi.org/10.1542/peds.111.4.745
- de Jong JA, Verkooijen HM, Valk GD, Zelissen PM, de Keizer B. High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover. Clin Nucl Med 2013;38(6):401-6. https://doi.org/10.1097/RLU.0b013e3182817c78
- Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine ((1)(3)(1)I) doses for Graves disease treatment. Clin Nucl Med 2012;37(3):241-4. https://doi.org/10.1097/RLU.0b013e31823ea6e0
- Moura-Neto A, Mosci C, Santos AO, Amorim BJ, de Lima MC, Etchebehere EC, et al. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease. Clin Nucl Med 2012;37(6):550-4. https://doi.org/10.1097/RLU.0b013e31824851d1
- Lee HS, Min H. Iodine intake and tolerable upper intake level of iodine for Koreans. Korean J Nutr 2011;44(1):82-91. https://doi.org/10.4163/kjn.2011.44.1.82
피인용 문헌
- Utility of outpatient fractionated radioiodine therapy for Graves disease involving a large goiter measuring more than 100 mL in volume vol.68, pp.9, 2018, https://doi.org/10.1507/endocrj.ej20-0836